General MedicationsORALStandard
TRYVIO
APROCITENTAN
Standard Dose
12.5MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary
Approval overview TRYVIO is listed in Drugs@FDA under application 217686 (NDA).
Review priority: N/A Marketing status: Prescription Active ingredient APROCITENTAN Form and strength TABLET;ORAL - 12.5MG Sponsor IDORSIA Submission history Latest submission status date: 2025-04-02 00:00:00.
Structured Monograph
Clinical summary
Approval overview TRYVIO is listed in Drugs@FDA under application 217686 (NDA). Review priority: N/A Marketing status: Prescription Active ingredient APROCITENTAN Form and strength TABLET;ORAL - 12.5MG Sponsor IDORSIA Submission history Latest submission status date: 2025-04-02 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: N/A
Interaction Notes
- No interaction notes stored yet.